Año 2023 / Volumen 115 / Número 2
Original
Prevalence of non-alcoholic fatty liver disease in pediatric mental disorder inpatients: a tertiary mental health referral hospital study

64-69

DOI: 10.17235/reed.2022.8986/2022

Lini Liu, Rongrong Tan, Zhenghua Fang, Li Li, Xi Chen, Yinli Luo, Dong Yang,

Resumen
Background and aim: Studies have revealed a high prevalence of non-alcoholic fatty liver disease (NAFLD) among adult patients with mental disorders, as well as its associate risk factors, however little is known about these in pediatric population. The aim of the present study is to investigate the prevalence of NAFLD in pediatric inpatients with mental disorder, as well as to explore the risk factors. Methods: In this retrospective study, we included 1156 pediatric inpatients with mental disorder admitted to our hospital between January 2020 and December 2021, including inpatients with schizophrenia, bipolar disorder, depressive disorder and other mental disorders. Relevant clinical data were obtained from the electronic medical records. We calculated the prevalence rate of NAFLD, and compared NAFLD prevalence between gender, mental disorders types, antipsychotics use, and comorbidities. Multivariable logistic regression was used to examine risk factors associated with NAFLD. Results: The prevalence of NAFLD in pediatric inpatients with mental disorders was 7.35% (85/1156). Patients with NAFLD had senior age than those without NAFLD (15.33±1.75 vs 14.21±1.95 year-old, P<0.001). The NAFLD prevalence in participants with schizophrenia (12.11%) was higher than in participants with bipolar disorder (8.45%), depressive disorder (7.06%) and other mental disorders (2.97%)(p=0.002). The NAFLD prevalence was higher in participants who used antipsychotics (8.70%) than those who didn't (5.45%) (p=0.038). Multivariate analysis revealed that senior age, body weight (overweight/obese) and dyslipidemia were independent risk factors for NAFLD in pediatric inpatients with mental disorders. Conclusions: The NAFLD prevalence was is higher in those patients with schizophrenia and receiving antipsychotic medication. Metabolic factors and longer evolution may explain these differences.
Share Button
Nuevo comentario
Comentarios
No hay comentarios para este artículo.
Bibliografía
1. Shapiro WL, Noon SL, Schwimmer JB. Recent advances in the epidemiology of nonalcoholic fatty liver disease in children. Pediatr Obes 2021;16:e12849.
2. Brecelj J, Orel R. Non-Alcoholic Fatty Liver Disease in Children. Medicina (Kaunas) 2021;57:719.
3. Nobili V, Alisi A, Newton KP, et al. Comparison of the Phenotype and Approach to Pediatric vs Adult Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2016;150:1798-810.
4. Crespo M, Lappe S, Feldstein AE, et al. Similarities and differences between pediatric and adult nonalcoholic fatty liver disease. Metabolism 2016;65:1161-71.
5. Kistler KD, Molleston J, Unalp A, et al; Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN). Symptoms and quality of life in obese children and adolescents with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2010; 31:396-406.
6. Mazzone L, Postorino V, De Peppo L, et al. Paediatric non-alcoholic Fatty liver disease: impact on patients and mothers' quality of life. Hepat Mon 2013;13:e7871.
7. Kerkar N, D'Urso C, Van Nostrand K, et al. Psychosocial outcomes for children with nonalcoholic fatty liver disease over time and compared with obese controls. J Pediatr Gastroenterol Nutr 2013;56(1):77-82.
8. Karaivazoglou K, Kalogeropoulou M, Assimakopoulos S, et al. Psychosocial Issues in Pediatric Nonalcoholic Fatty Liver Disease. Psychosomatics 2019;60:10-17.
9. Penninx BWJH, Lange SMM. Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications. Dialogues Clin Neurosci 2018;20:63-73.
10. Vancampfort D, Stubbs B, Mitchell AJ, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry 2015;14:339-47.
11. Morlán-Coarasa MJ, Arias-Loste MT, Ortiz-García de la Foz V, et al. Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study. Psychopharmacology (Berl) 2016;233:3947-3952.
12. Godin O, Leboyer M, Belzeaux R, et al; FondaMental Advanced Centers of Expertise in Bipolar Disorders (FACE-BD) Collaborators. Non-alcoholic fatty liver disease in a sample of individuals with bipolar disorders: results from the FACE-BD cohort. Acta Psychiatr Scand 2021;143:82-91.
13. Kim D, Yoo ER, Li AA, et al. Depression is associated with non-alcoholic fatty liver disease among adults in the United States. Aliment Pharmacol Ther 2019; 50:590-598.
14. Gu Y, Zhang W, Hu Y, et al. Association between nonalcoholic fatty liver disease and depression: A systematic review and meta-analysis of observational studies. J Affect Disord 2022;301:8-13.
15. Ma Q, Yang F, Ma B, et al. Prevalence of nonalcoholic fatty liver disease in mental disorder inpatients in China: an observational study. Hepatol Int 2021;15:127-136.
16. Yan J, Hou C, Liang Y. The prevalence and risk factors of young male schizophrenics with non-alcoholic fatty liver disease. Neuropsychiatr Dis Treat 2017; 13:1493-1498.
17. World Health Organization. International Statistical Classification of Diseases and Health Related Problems, 10th revision [Chinese version]. Beijing: People’s Medical Publishing House; 1996.
18. Wong VW, Chan WK, Chitturi S, et al. Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: definition, risk factors and assessment. J Gastroenterol Hepatol 2018;33:70–85.
19. US Preventive Services Task Force, Grossman DC, Bibbins-Domingo K, Curry SJ, et al. Screening for Obesity in Children and Adolescents: US Preventive Services Task Force Recommendation Statement. JAMA 2017;317:2417-2426.
20. Gallagher, D. A Guide to Methods for Assessing Childhood Obesity. Washington (DC): National Collaborative on Childhood Obesity Research. June 2020. https://www.nccor.org/tools-assessingobesity [Accessed April 28, 2022].
21. Anderson EL, Howe LD, Jones HE, et al. The Prevalence of Non-Alcoholic Fatty Liver Disease in Children and Adolescents: A Systematic Review and Meta-Analysis. PLoS One 2015;10:e0140908.
22. Li J, Le MH, Barakat MT, et al. The Changing Epidemiology of Liver Disease Among US Children and Adolescents From 1999 to 2016. Am J Gastroenterol 2021;116:2068-2078.
23. Rong Y, Chun-Yan N, Hong-Xin Z, et al. Association of Adolescent Obesity with Nonalcoholic Fatty Liver Disease and Related Risk Factors in Xi 'an, China. Ann Hepatol 2018;17:85-91.
24. Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol 2018;69:896-904.
25. Li Z, Xue J, Chen P, et al. Prevalence of nonalcoholic fatty liver disease in mainland of China: a meta-analysis of published studies. J Gastroenterol Hepatol 2014;29:42-51.
26. Koreki A, Mori H, Nozaki S, et al. Risk of Nonalcoholic Fatty Liver Disease in Patients With Schizophrenia Treated With Antipsychotic Drugs: A Cross-sectional Study. J Clin Psychopharmacol 2021;41:474-477.
27. Bernier E, Vary CPH, May M, et al. Understanding Mechanisms Underlying Non-Alcoholic Fatty Liver Disease (NAFLD) in Mental Illness: Risperidone and Olanzapine Alter the Hepatic Proteomic Signature in Mice. Int J Mol Sci 2020;21:9362.
28. Li R, Zhu W, Huang P, et al. Olanzapine leads to nonalcoholic fatty liver disease through the apolipoprotein A5 pathway. Biomed Pharmacother 2021;141:111803.
29. Thiagarajan S, Shrinuvasan S, Arun Babu T. Screening for non-alcoholic fatty liver disease among obese and overweight children: Prevalence and predictors. Indian J Gastroenterol 2022;41:63-68.
30. Querter I, Pauwels NS, De Bruyne R, et al. Maternal and Perinatal Risk Factors for Pediatric Nonalcoholic Fatty Liver Disease: A Systematic Review. Clin Gastroenterol Hepatol 2022;20:740-755.
Artículos relacionados

Imagen en Patología Digestiva

Esófago negro

DOI: 10.17235/reed.2022.9217/2022

Editorial

Trasplante de pulmón y disfunción esofágica

DOI: 10.17235/reed.2018.5693/2018

Original

Colonic diverticulosis and the metabolic syndrome: an association?

DOI: 10.17235/reed.2017.5009/2017

Instrucciones para citar
Liu L, Tan R, Fang Z, Li L, Chen X, Luo Y, et all. Prevalence of non-alcoholic fatty liver disease in pediatric mental disorder inpatients: a tertiary mental health referral hospital study. 8986/2022


Descargar en un gestor de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica
Este artículo ha sido visitado 1368 veces.
Este artículo ha sido descargado 98 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 05/06/2022

Aceptado: 19/10/2022

Prepublicado: 25/10/2022

Publicado: 07/02/2023

Tiempo de revisión del artículo: 127 días

Tiempo de prepublicación: 142 días

Tiempo de edición del artículo: 247 días


Compartir
Este artículo aun no tiene valoraciones.
Valoración del lector:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
La REED es el órgano oficial de la Sociedad Española de Patología Digestiva, la SociedadEspañola de Endoscopia Digestiva y la Asociación Española de Ecografía Digestiva
Política de cookies Política de Privacidad Aviso Legal © Copyright 2023 y Creative Commons. Revista Española de Enfermedades Digestivas